Key result
Sex differences in hypertension prevalence, risk factors, and treatment responses highlight the need for individualized therapeutic strategies to reduce cardiovascular mortality.
Why the study?
Despite well-documented sex differences in hypertension prevalence, risk factors, and treatment responses, current guidelines fail to account for these specificities.
Incorporating sex differences into hypertension management and guidelines is essential to enhance treatment efficacy and reduce cardiovascular mortality.
Sex differences in hypertension prevalence and responses challenge current guidelines; leaves open whether tailored strategies improve outcomes.
PURPOSE OF REVIEW: Hypertension is the most prevalent cardiovascular disease worldwide and the leading cause of mortality in both men and women. Despite well documented sex differences in prevalence, risk factors, and treatment responses, current guidelines still fail to take these specificities into account. A more tailored approach, accounting for sex-specific pathophysiological mechanisms and risk factors, is essential. RECENT FINDINGS: Studies show that hypertension is more prevalent in men than in women until menopause. After menopause, the prevalence increases in women, likely due to hormonal changes. Additionally, genetic, metabolic, and social risk factors differ between the sexes, as do cardiovascular risks and associated comorbidities. Pharmacokinetic and pharmacodynamic variations also impact antihypertensive treatment efficacy and side effects, highlighting the need for a more individualized therapeutic strategy. This review explores the pathophysiology of hypertension by sex, global risk factors with a focus on female-specific aspects, and sex-related cardiovascular risks. We also discuss antihypertensive treatments and their effectiveness based on gender-specific characteristics. SUMMARY: Incorporating sex differences into hypertension management could enhance treatment efficacy and reduce cardiovascular mortality. Further research is needed to refine guidelines and develop personalized therapeutic strategies, optimizing hypertension care and improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Bourdon et al. (2025) conducted a review in Hypertension. Sex differences was evaluated. Sex differences in hypertension prevalence, risk factors, and treatment responses highlight the need for individualized therapeutic strategies to reduce cardiovascular mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: